


Supplemental Figure S1. Responses to anti-CD19 CAR T-cell therapy. (A) Procedure of CAR T cell manufacture and the clinical application scheme. Lymphocyte-depleting chemotherapy with FC regimen consisted of 25 mg/m² Fludarabine (Flu) and 300mg/m² cyclophosphamide (Cy) daily for 3 days. The patient received a total of 2 × 10⁶ T cells/kg (0.8 × 10⁶ CAR T cells/kg), split into three consecutive daily intravenous infusions (10% on day 0, 30% on day 1, and 60% on day 2). (B) Changes in daily maximum temperature and C-reactive protein (CRP) are shown within 28 days after CAR T-cell infusions. (C) Changes of serum cytokines are shown on indicated day after CAR T-cell infusions. IL-2, interleukin 2; IL-4, interleukin 4; IL-6, interleukin 6; IL-10, interleukin 10; TNF- α , tumor necrosis factor α ; IFN- γ , interferon γ .



Supplemental Figure S2 The serum levels of IgG, IgA and IgM are shown by indicated time points during the 48-month duration of follow-up.